CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case–control study

Author： Miroševic Skvrce Nikica   Božina Nada   Zibar Lada   Barišic Ivan   Pejnovic Lana   Macolic Šarinic Viola  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.12, 2013-09, pp. : 1419-1431

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study

By  

Current Clinical Pharmacology, Vol. 11, Iss. 1, 2016-02 ,pp. : 62-68

Bentham Science Publishers

Access to resources Recommend Favorite

Warfarin: CYP2C9 polymorphisms increase risk of bleeding events

By  

Inpharma, Vol. 1, Iss. 1333, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment

By Gschwind Liliane   Rollason Victoria   Boehlen Françoise   Rebsamen Michela   Combescure Christophe   Grünenwald Michèle   Matthey Alain   Bonnabry Pascal   Dayer Pierre   Desmeules Jules Alexandre  

Pharmacogenomics, Vol. 14, Iss. 7, 2013-05 ,pp. : 745-753

Future Medicine

Access to resources Recommend Favorite

Influence of Cytochrome P450 (CYP) 3A5 Polymorphisms on the Pharmacokinetics of Lansoprazole Enantiomers in CYP2C19 Extensive Metaboliser Renal Transplant Recipients

By Miura Masatomo  

Clinical Drug Investigation, Vol. 27, Iss. 4, 2007-01 ,pp. : 251-258

Adis International

Access to resources Recommend Favorite

Pharmacogenetic Prediction of Individual Variability in Drug Response Based on CYP2D6, CYP2C9 and CYP2C19 Genetic Polymorphisms

By  

Current Drug Metabolism, Vol. 15, Iss. 7, 2014-09 ,pp. : 711-718

Bentham Science Publishers

Access to resources Recommend Favorite